Illumina, Inc.
Provides next-generation DNA sequencing systems, consumables, software, and services for genomics research and clinical applications.
Website: https://www.illumina.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Illumina, Inc. |
| Tagline | Provides next-generation DNA sequencing systems, consumables, software, and services for genomics research and clinical applications. [Illumina] |
| Headquarters | San Diego, California, US [Illumina] |
| Founded | 1998 [Crunchbase] |
| Stage | Public |
| Business Model | Hardware + Software |
| Industry | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Founders | David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, Mark S. Chee [Crunchbase, David R. Walt] [Crunchbase, John Stuelpnagel] |
| Total Disclosed | $33.6 billion, related Crunchbase figure surfaced for Illumina Accelerator and treated cautiously here [Crunchbase, Illumina Accelerator] |
Links
Open sources
- Website: https://www.illumina.com/
- LinkedIn: https://www.linkedin.com/company/illumina/jobs
- Indeed: https://www.indeed.com/q-illumina-jobs.html
What an Investor Needs First
PUBLIC Illumina is a publicly traded genomics company that sells DNA sequencing instruments, consumables, software, and related services, and it merits attention because the business remains a central platform provider in next-generation sequencing while also trying to widen its software and clinical relevance [Illumina, Unknown] [Illumina, February 2026] [Fortune Business Insights]. Founded in 1998, the company emerged from licensed BeadArray technology associated with John R. Stuelpnagel and David R. Walt, then grew into one of the best-known infrastructure providers for genomic analysis [Crunchbase] [Crunchbase, David R. Walt]. Its core model is straightforward but durable: customers adopt sequencing systems such as NovaSeq X, NextSeq, and MiSeq, then continue purchasing consumables, prep products, informatics, and support, which gives the company a recurring revenue layer around an installed hardware base [The Motley Fool, February 2026] [CopiaSci] [Illumina, Unknown].
The differentiation, based on the public record, rests less on a single point product than on breadth across instruments, consumables, software, and workflow integration, including the newer BioInsight software push and the Billion Cell Atlas consortium announced in 2026 [Illumina, 2025] [Illumina, July 2026] [TradingView News, October 2026]. Founder pedigree is also relevant here: Walt is listed by Crunchbase as Illumina's scientific founder and has a long academic and commercialization record, while Stuelpnagel's Crunchbase profile ties him directly to the licensing of the underlying BeadArray technology that led to the company's formation [Crunchbase, David R. Walt] [Crunchbase]. Illumina's capital structure is now that of a public company rather than a venture-backed startup, so conventional private-round analysis is less useful than operating performance, and recent public disclosures point to Q4 2025 revenue of $1.16 billion and continued NovaSeq X adoption, with roughly 80% of sequencing volumes and 55% of revenue transitioned to that platform by Q4 2025 according to management commentary [Illumina Press Release, February 2026] [Yahoo Finance].
Over the next 12 to 18 months, the key watch items are whether software and data products contribute meaningfully beyond the instrument-and-consumables base, whether the NovaSeq X transition continues to support margin expansion, and how much of Illumina's position in a concentrated NGS market proves durable as newer platform competitors push on throughput and cost [Yahoo Finance, October 2026] [Fortune Business Insights] [DeciBio]. Public evidence suggests a company with scale, category relevance, and a still-evolving platform story, but the pace of software monetization and the defensibility of sequencing share remain the central variables to monitor [Illumina, Unknown] [Illumina, 2025] [Fortune Business Insights].
Partially corroborated -- This section relies on company materials, earnings-related coverage, and Crunchbase, with several operating and market-position claims supported by single sources or management commentary.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Public |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
Inside the Company
PUBLIC
Illumina, Inc. traces back to April 1998, when the company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee [Crunchbase, April 2025]. The company is headquartered in San Diego, California, and presents itself as a genomics company focused on sequencing and array-based tools used across life science research, translational and consumer genomics, and molecular diagnostics [Crunchbase, April 2025] [Illumina].
The current business is broader than an instrument vendor. On its website, Illumina describes a product stack spanning sequencing systems, consumables, software, and services, with solutions used in disease research, drug discovery, and clinical laboratory testing [Illumina]. That framing matters because it helps explain the company’s long-standing model: hardware placements supported by recurring demand for consumables and informatics tied to genomic workflows, although the recurring revenue mix itself is not quantified in the sources used here [Illumina].
Public milestones in the supplied record are selective but directionally clear. Illumina’s website shows a continued expansion from core sequencing into software and startup ecosystem programs, including Illumina for Startups and, by 2025 to 2026, BioInsight and the Billion Cell Atlas initiative as newer extensions around data and analysis workflows [Illumina] [Illumina, 2025] [Illumina, July 2026]. The legal entity name is established as Illumina, Inc., while the available sources for this section do not add state filing detail beyond the corporate identity reflected on the company’s site and Crunchbase profile [Illumina] [Crunchbase, April 2025].
Partially corroborated -- Confirmed primarily by Crunchbase and Illumina corporate materials; milestone chronology beyond founding and headquarters relies mainly on company sources.
Under the Hood
MIXED
What stands out first is not a single instrument, but the breadth of the stack. Illumina presents itself as a genomics platform company that sells sequencing and array products for research, translational and consumer genomics, and molecular diagnostics, with offerings that span instruments, consumables, software, and services [Illumina]. The company says its solutions support disease research, drug discovery, and molecular test development in clinical labs, which places the business squarely in a recurring hardware-plus-consumables model rather than a one-time equipment sale [Illumina].
The named product surfaces in the public record support that framing. Illumina's product catalog describes a broad range of sequencing and microarray products for genomic analysis applications [Illumina], and third-party coverage identifies NextSeq and MiSeq among its DNA sequencers [CopiaSci]. For high-throughput work, management described NovaSeq X as a platform for large-scale genomic and multiomic applications, and by Q4 2025 said roughly 80% of sequencing volumes and 55% of revenue had transitioned to NovaSeq X, with research migration nearing 90% of high-throughput volumes [The Motley Fool, February 2026] [Yahoo Finance].
Illumina is also trying to make software a more visible part of the product story. On its website, the company says BioInsight Platform Core uses cloud resources for data storage and compute, and allows users to run DRAGEN pipelines, build custom pipelines, perform interactive analyses, and query cohort data [Illumina]. Public materials also show a formal BioInsight business unit, led by senior vice president and general manager Rami Mehio, while 2026 press and earnings-related coverage ties that software layer to the Billion Cell Atlas initiative, a consortium effort launched in January 2026 with participants including AstraZeneca, Eli Lilly, Formation Bio, Merck, and, according to later coverage, GSK [Illumina, July 2026] [Illumina, 2025] [TradingView News, October 2026].
That product architecture matters because it suggests Illumina is defending the installed base on two fronts at once. The core remains proprietary sequencing systems plus recurring consumables [Illumina], but the software layer and consortium data efforts indicate an effort to capture more workflow value above the instrument, especially in clinical informatics and AI-linked biological data generation [WhatJobs.com, 2026] [TradingView News, October 2026]. The evidence is stronger for the existence of these products and programs than for their standalone commercial traction, so the conservative read is that software expansion is real, but its economic weight relative to sequencing is still only partly visible in public filings and press.
Partially corroborated -- Based on company website and company press materials, with partial corroboration from earnings-call coverage and third-party product references.
Market Research
PUBLIC
Genomics tools remain a consequential market because demand is no longer confined to basic research, it now spans clinical testing, drug discovery, and applied biology workflows that require both instrument capacity and repeat consumables spend [Illumina, Unknown].
Public source support for a formal TAM, SAM, and SOM is limited in the materials provided, so the cleaner approach is to use adjacent market evidence rather than force precision the record does not support. Fortune Business Insights describes the next-generation sequencing market in 2024 as highly consolidated, with Illumina, Thermo Fisher Scientific, and F. Hoffmann-La Roche capturing the majority of share [Fortune Business Insights]. MarketsandMarkets, looking at the related next-generation sequencing services market, says products led the market in 2024 while services are expected to post the fastest growth, at an 18.0% CAGR [MarketsandMarkets]. That distinction matters because it implies a market still anchored by instrument and consumables sales, but with an expanding downstream services and software layer.
The clearest demand drivers in the cited record are breadth of use case and workflow migration. Illumina’s own description of its business ties genomic analysis tools to disease research, drug discovery, and molecular testing in clinical labs [Illumina, Unknown]. On the company-specific side, management said roughly 80% of volumes and 55% of revenue had transitioned to NovaSeq X by Q4 2025, with about 90% of high-throughput research sequencing volumes already on the platform [Yahoo Finance]. That is not a market-size datapoint, but it is a useful read-through that high-throughput customers are still refreshing systems when throughput, cost, or multiomics capability improves [The Motley Fool, February 2026].
Adjacent markets are becoming harder to separate from core sequencing. The product catalog spans sequencing and microarray products for genomic analysis applications [Illumina, Unknown], while newer company initiatives point toward informatics and data-platform demand as an incremental layer on top of wet-lab infrastructure. BioInsight Platform Core uses cloud resources for storage and compute, and allows access to DRAGEN pipelines, custom pipeline development, interactive analyses, and cohort queries, according to Illumina product materials [Illumina, Unknown]. The Billion Cell Atlas program, launched in January 2026, is positioned around standardized biological datasets for AI-driven drug discovery, with AstraZeneca, Eli Lilly, Formation Bio, Merck, and later GSK cited as participants or members [Illumina, July 2026] [TradingView News, October 2026]. The market implication is straightforward: sequencing vendors are increasingly competing not only in hardware, but also in data generation, analysis environments, and pharma-facing discovery workflows.
Macro and regulatory forces cut both ways. Clinical genomics benefits from continued use in molecular testing and translational research, but large platform vendors also operate in a more politically exposed environment, where reimbursement, laboratory regulation, cross-border trade, and China-related market access can affect demand and reported revenue mix. Illumina’s own reporting now highlights ex-China revenue separately, with Q4 2025 ex-China revenue of $1.10 billion on total quarterly revenue of $1.16 billion [Illumina Press Release, February 2026]. That does not establish a sector-wide conclusion on its own, though it does suggest geography and policy are material enough to warrant explicit segmentation.
| Market or Segment Claim | Value | Source |
|---|---|---|
| NGS market structure in 2024 | Majority share held by Illumina, Thermo Fisher Scientific, and Roche | [Fortune Business Insights] |
| NGS services market, fastest-growing segment | Services CAGR 18.0% | [MarketsandMarkets] |
| Illumina platform transition, Q4 2025 | 80% of volumes on NovaSeq X | [Yahoo Finance] |
| Illumina platform transition, Q4 2025 | 55% of revenue on NovaSeq X | [Yahoo Finance] |
| Research high-throughput transition, Q4 2025 | About 90% of volumes on NovaSeq X | [Yahoo Finance] |
The table shows a market with two layers moving at once: concentration at the platform level, and faster growth in services and analytics around the installed base. For operators and investors, that usually means the next phase of value capture depends less on selling the first box and more on owning recurring workflow spend.
Partially corroborated -- Section relies on one third-party market-structure source, one third-party segment-growth source, and company-linked operating datapoints that are relevant but not independent market sizing evidence.
Competition and Substitutes
Competitive Set
MIXED Illumina still sits at the center of next-generation sequencing, but the current competitive picture is less about whether alternatives exist and more about which parts of the workflow competitors can peel away without displacing the core instrument base [Fortune Business Insights] [Illumina, Unknown] [The Motley Fool, February 2026].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Illumina, Inc. | Public genomics platform spanning sequencing instruments, consumables, software, and services for research, clinical, and applied markets | Public company | Broad installed-base model, with recurring pull-through from consumables and a growing software layer including BioInsight and DRAGEN-linked workflows | [Illumina, Unknown] [Illumina, 2025] [The Motley Fool, February 2026] |
| Thermo Fisher Scientific | Diversified life sciences incumbent with sequencing exposure inside a larger tools portfolio | Public company | Category breadth across instruments, reagents, and lab workflows, which can support bundled purchasing in enterprise accounts | [Fortune Business Insights] |
| F. Hoffmann-La Roche Ltd. | Large diagnostics and life sciences incumbent participating in NGS | Public company | Clinical and diagnostics footprint, relevant where sequencing decisions tie closely to regulated testing environments | [Fortune Business Insights] |
| PacBio | Sequencing specialist competing on read architecture rather than full-market breadth | Public company | Distinct sequencing approach that can matter in use cases where standard short-read workflows are less sufficient | [CopiaSci] |
| Element Biosciences | Emerging sequencing challenger named alongside newer platform competitors | Private company | Challenger positioning around newer instrument choice for labs evaluating alternatives to the incumbent stack | [MatrixBCG.com] |
| Ultima Genomics | Emerging sequencing challenger named in the current competitive set | Private company | Competes for large-scale sequencing economics, particularly where buyers are reassessing cost at very high throughput | [MatrixBCG.com] |
The table points to a market with two layers. At the top are diversified incumbents such as Thermo Fisher and Roche, both of which can use broader commercial relationships to win share in institutional accounts [Fortune Business Insights]. Underneath them is a class of sequencing specialists and challengers, including PacBio, Element Biosciences, Ultima Genomics, Singular Genomics, MGI or Complete Genomics, and Agilent, each pushing on a narrower wedge such as workflow fit, instrument architecture, or economics in selected use cases [MatrixBCG.com] [CopiaSci].
Illumina's defensible edge today appears to rest on distribution and ecosystem depth rather than on any single product claim. The company sells instruments, consumables, informatics software, and services across research, clinical, and applied markets, which gives it multiple attachment points inside the same account [Illumina, Unknown] [Illumina, Unknown]. That matters because the migration to NovaSeq X already looks substantial: as of Q4 2025, roughly 80% of volumes and 55% of revenue had transitioned to NovaSeq X, while about 90% of high-throughput research volumes had moved to the platform, according to earnings-call coverage [Yahoo Finance]. More than 80 NovaSeq X instruments were placed in Q3 2026 and about 360 over the prior four quarters, again according to earnings-call coverage, which suggests the installed base is still refreshing rather than merely defending legacy placements [Yahoo Finance, October 2026].
That edge is meaningful, but it is not permanent. Consumables pull-through and workflow familiarity can make incumbency durable, especially in regulated or validation-heavy environments, yet newer competitors only need to win a subset of high-value workloads to change purchasing behavior at the margin [Illumina, Unknown] [Fortune Business Insights]. Illumina's push into software and data infrastructure through BioInsight, alongside the Billion Cell Atlas consortium with partners including AstraZeneca, Eli Lilly, Formation Bio, Merck, GSK, and others, looks like an attempt to make the moat more than hardware-deep [Illumina, 2025] [Illumina, July 2026] [TradingView News, October 2026]. If that software layer becomes embedded in analysis and cohort workflows, the platform gets stickier. If it does not, the instrument layer remains more exposed to price and performance competition.
The clearest exposure is at the high-throughput frontier, where challengers can frame the buying decision around economics or architecture rather than brand familiarity. Ultima Genomics is the most obvious named threat if procurement teams prioritize cost per genome at scale, while PacBio is the named threat when buyers need read characteristics that standard short-read systems do not fully address [MatrixBCG.com] [CopiaSci]. Roche and Thermo Fisher present a different kind of risk: not a single-platform knockout, but share erosion through broader procurement use and clinical-lab relationships [Fortune Business Insights]. Illumina also does not control every adjacent channel. Services are expected to post the highest CAGR in the next-generation sequencing services market, at 18.0%, according to MarketsandMarkets, while products dominated in 2024 [MarketsandMarkets]. That leaves room for value to accrue outside the core instrument sale if third parties capture more downstream analysis, testing, or managed-service spend.
Over the next 18 months, the most plausible scenario is continued incumbent strength in core short-read sequencing, paired with selective pressure at the margins. Illumina is the likely winner if NovaSeq X placements continue translating into consumables and software attachment, and if BioInsight or Billion Cell Atlas improves switching costs beyond the hardware estate [Yahoo Finance, October 2026] [Illumina, July 2026]. A more vulnerable player in that scenario would be a newer challenger such as Singular Genomics or Element Biosciences if the market rewards installed-base trust and workflow continuity over experimentation [MatrixBCG.com]. The reverse case is narrower but credible: Ultima Genomics is the winner if very large buyers re-open platform decisions primarily on sequencing economics, and Illumina becomes the relative loser if migration to newer alternatives starts first in the highest-volume accounts where consumables pull-through matters most [MatrixBCG.com] [Yahoo Finance, October 2026].
Partially corroborated -- Core competitive structure is supported by public company materials and third-party market reports, but several competitor-specific positioning claims rely on single-source coverage or category summaries rather than direct company disclosures.
Opportunity
PUBLIC
The size of the prize is unusually large because Illumina already sits at the core of a sequencing market that remains concentrated, and the next layer of value appears to be shifting from instruments into software, clinical workflows, and large biological datasets [Fortune Business Insights] [MarketsandMarkets] [Illumina Press Release, February 2026].
The headline opportunity is straightforward: Illumina could extend from being the dominant supplier of next-generation sequencing hardware and consumables into the default operating layer for genomic analysis and multiomic data workflows. That outcome is reachable, not merely aspirational, because the installed-base transition is already visible in the public record. As of Q4 2025, roughly 80% of sequencing volumes and 55% of revenue had transitioned to NovaSeq X, and management said about 90% of high-throughput research sequencing volumes were already on NovaSeq X [Yahoo Finance]. In Q3 2026, Illumina placed more than 80 NovaSeq X instruments and about 360 over the prior four quarters, while also reporting operating margin expansion to 25%, which suggests the company is still converting platform adoption into financial use rather than buying growth at any cost [Yahoo Finance, October 2026] [Yahoo Finance, October 2026].
A second leg of the opportunity is software and data. Illumina says BioInsight Platform Core uses cloud resources for storage and compute, and gives bioinformaticians access to DRAGEN pipelines, custom pipeline development, interactive analyses, and cohort querying [Illumina]. The company also launched the Billion Cell Atlas program in January 2026, with consortium members including AstraZeneca, Eli Lilly, Formation Bio, Merck, and later cited participation from GSK, which matters because proprietary, standardized biological datasets can raise switching costs well beyond the sequencer itself if they become embedded in drug discovery and clinical research workflows [Illumina, July 2026] [TradingView News, October 2026].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| NovaSeq X becomes the enduring high-throughput standard | Illumina completes the research transition and deepens recurring consumables pull-through from an expanded instrument base | The visible migration of volume to NovaSeq X, plus continued placements in 2026 [Yahoo Finance] [Yahoo Finance, October 2026] | Public disclosures already show high-throughput research customers moving onto NovaSeq X at scale, with 80% of volumes and 90% of research high-throughput volumes transitioned by Q4 2025 [Yahoo Finance] |
| BioInsight becomes the software control plane for genomics workflows | Illumina captures a larger share of value per customer through analysis, cloud compute, and workflow orchestration layered on top of sequencing | BioInsight business formation and productization of DRAGEN-access, cohort query, and custom pipeline capabilities [Illumina] [WhatJobs.com, 2026] | The company already sells software-linked functionality and support tiers, and has assigned dedicated leadership to BioInsight under Rami Mehio [Illumina] [Illumina, 2025] |
| Billion Cell Atlas becomes a strategic data asset | Illumina moves upstream into dataset creation for AI-enabled drug discovery, making its platform more central to pharma R&D | Expansion of the consortium with major drug companies and continued dataset standardization efforts [Illumina, July 2026] [TradingView News, October 2026] | Named pharmaceutical participants indicate early willingness from large buyers to engage on shared data infrastructure, not just instrument procurement [Illumina, July 2026] |
The compounding mechanism is the familiar one in life-science tools, but Illumina has a chance to make it broader. Instruments seed the lab, consumables create recurring revenue, software becomes embedded in daily analysis, and shared datasets can increase the value of staying on the same stack. The public evidence for that flywheel is partial but real: hardware migration is already under way through NovaSeq X [Yahoo Finance] [Yahoo Finance, October 2026], the products segment still dominates the broader NGS services market according to MarketsandMarkets [MarketsandMarkets], and the services segment is expected to grow faster at an 18.0% CAGR, which supports the idea that higher-value analysis and workflow layers can become a larger part of the profit pool over time [MarketsandMarkets].
The size of the win, if that stack extension works, is best framed against public category leaders rather than a startup-style TAM slide. One external source places Illumina's market capitalization in a $20 billion to $30 billion range after its multi-cancer divestiture, although that figure is only singly sourced and should be treated cautiously [MatrixBCG.com]. Another external source says Illumina's growth is forecast to trail the market by only about 2% annually, which implies a mature leader that still has room to capture adjacent layers rather than a business in structural retreat [DeciBio]. On that basis, a plausible upside case is not merely defending the installed base, but re-rating as a more software- and data-enriched genomics infrastructure company. That could support value creation above a pure tools multiple if BioInsight and Billion Cell Atlas gain adoption, though any valuation range here remains a scenario, not a forecast [Illumina, July 2026] [Illumina, 2025] [DeciBio].
Partially corroborated -- This section relies on a mix of company disclosures, earnings-call summaries, and third-party market reports, with several core operating claims corroborated by more than one public source but upside framing still partly dependent on company-led initiatives.
Sources
Open sources
[Illumina, February 2026] Illumina reports financial results for fourth quarter and fiscal year 2025 | https://www.illumina.com/company/news-center/press-releases/2026/5dc3da71-77d9-4286-8c21-70c83aacbcdc.html
[Fortune Business Insights] Next-generation sequencing market | https://www.fortunebusinessinsights.com/industry-reports/next-generation-sequencing-ngs-market-101000
[Crunchbase, April 2025] Illumina company profile | https://www.crunchbase.com/organization/illumina
[Crunchbase, David R. Walt] David R. Walt | https://www.crunchbase.com/person/david-r-walt
[Illumina, 2025] Illumina appoints Rami Mehio to lead BioInsight | https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=bac27a69-7339-4f9f-9c1e-1fbc262895d4
[Illumina, July 2026] Illumina Billion Cell Atlas program press release | https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=27191
[TradingView News, October 2026] ILMN Q3 earnings call highlights: higher guidance and clinical growth | https://www.tradingview.com/news/zacks:a92a19451094b:0-ilmn-q3-earnings-call-highlights-higher-guidance-and-clinical-growth/
[The Motley Fool, February 2026] Illumina (ILMN) Q4 2025 earnings call transcript | https://www.fool.com/earnings/call-transcripts/2026/02/05/illumina-ilmn-q4-2025-earnings-call-transcript/
[CopiaSci] Top DNA sequencer brands compared: Illumina, Thermo Fisher, Agilent, PacBio | https://www.copiasci.com/blog/blogs-1/top-dna-sequencer-brands-compared-illumina-thermo-fisher-agilent-pacbio-22
[Illumina] Sequencing and array solutions to fuel genomic discoveries | https://www.illumina.com/
[Crunchbase, John Stuelpnagel] John Stuelpnagel | https://www.crunchbase.com/person/john-stuelpnagel
[Yahoo Finance] Illumina Q4 earnings call highlights | https://finance.yahoo.com/news/illumina-q4-earnings-call-highlights-015802291.html
[MarketsandMarkets] Next-generation sequencing services market | https://www.marketsandmarkets.com/Market-Reports/ngs-services-market-194102241.html
[MatrixBCG.com] What is brief history of Illumina company? | https://matrixbcg.com/blogs/brief-history/illumina
[Yahoo Finance, October 2026] Illumina Q3 earnings call highlights | https://finance.yahoo.com/healthcare/articles/illumina-q3-earnings-call-highlights-221446722.html
[WhatJobs.com, 2026] What does Illumina do? | https://www.whatjobs.com/news/what-does-illumina-do/
[Illumina Press Release, February 2026] Illumina reports financial results for fourth quarter and fiscal year 2025 | https://www.illumina.com/company/news-center/press-releases/2026/5dc3da71-77d9-4286-8c21-70c83aacbcdc.html
Articles about Illumina, Inc.
- Illumina's BioInsight Unit Now Serves a Consortium of Pharma Giants — The sequencing giant's new software push aims to turn genomic data into a recurring revenue stream beyond the instrument sale.